Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.

@article{SezLlorens2015ImmunogenicityAS,
  title={Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.},
  author={Xavier S{\'a}ez-Llorens and Diana Catalina Aguilera Vaca and Katia Abarca and Emmanuelle Maho and Maria Gabriela Gra{\~n}a and Esther Heijnen and Igor V Smolenov and Peter M. Dull},
  journal={Human vaccines & immunotherapeutics},
  year={2015},
  volume={11 6},
  pages={1507-17}
}
This phase 2 study assessed the immunogenicity, safety, and reactogenicity of investigational formulations of meningococcal ABCWY vaccines, consisting of recombinant proteins (rMenB) and outer membrane vesicle (OMV) components of a licensed serogroup B vaccine, combined with components of a licensed quadrivalent meningococcal glycoconjugate vaccine (MenACWY-CRM). A total of 495 healthy adolescents were randomized to 6 groups to receive 2 doses (Months 0, 2) of one of 4 formulations of rMenB… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…